

Hospital Information (including name, address, telephone number)

Patient information (including name, address, date of birth, phone number)

Clinic information (including clinic name and telephone number)

Allergies (*also specify reaction*)

None known

Patient Name _____

BMP (*bortezomib-melphalan-predniSONE*)*

**drug in italics is IV drug given in hospital or cancer centre*

Cycle #: _____; Cycles repeat every 35 or 42 days

Height = _____ cm Weight = _____ kg

Body Surface Area (BSA) = _____ m²

Diagnosis: Multiple myeloma

Clinical Verification

Bloodwork and other clinical parameters have been verified by a regulated health professional

Date Print name Signature

Prescription has been verified by an nurse or pharmacist

Date Print name Signature

Rx (Start Date/Day 1: _____)

melphalan 9 mg/m² x BSA x _____% dose* = _____ mg PO daily on Days 1 to 4

Mitte: _____ x 2 mg tablets (ODB general benefit)

AND

predniSONE 60 mg/m² x _____% dose* = _____ mg PO daily in the morning with food on Days 1 to 4

Mitte: _____ x 50 mg tablets (ODB general benefit)

*Dose modification (s) for: Age/performance status Hematologic toxicity Renal function Hepatic function

Other toxicity _____

NO Repeats

Supportive Care Rx

prochlorperazine 10 mg PO q6h PRN nausea Mitte: _____ Repeat: _____

Antiviral prophylaxis (if applicable, specify drug, dose, frequency): _____

Mitte: _____ Repeat: _____

Date Print name Physician Signature CPSO#

Prescriber information (name, office phone number/fax, address if different than hospital address)

Pharmacist information (name, office phone number/fax)

OPTIONAL INFORMATION

- Patient has been counseled by an Oncology Pharmacist

OR

_____	_____	_____
Print name	Signature	Date

- Requires counseling
 Drug interaction assessment

Drug-specific information

For the complete information, please refer to the Cancer Care Ontario drug information sheets available at www.cancercare.on.ca/drugformulary